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Abstract Some low molecular mass heat shock proteins (HSPs)
appear to act as molecular chaperones, but their exact
physiological roles have not been fully elucidated. We reported
previously that a 20-kDa protein (p20), which is classified as a
low molecular mass HSP, is present at high levels in skeletal and
smooth muscles. In the present study, we investigated a
physiological role of p20 on platelet function in vitro and ex
vivo. p20 inhibited platelet aggregation using human platelets
dose-dependently induced by botrocetin. On the other hand,
HSP27, the other type of low molecular mass HSP, did not
affect platelet aggregation. When p20 (300 Wg/kg) was injected
intravenously as a bolus in hamsters, platelet aggregation ex vivo
induced by botrocetin was also significantly inhibited. In order to
further investigate the inhibitory effect by p20 on platelet
activation, we performed platelet aggregation induced by
thrombin or ADP using human platelets. p20 markedly prevented
platelet aggregation induced by thrombin, but not ADP. These
findings suggest that p20 can act intercellularly to regulate
platelet functions. Our results may provide the basis for a novel
defensive system to thrombus formation.
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1. Introduction
Heat shock proteins (HSPs), whose expression is induced by
many kinds of stress, protect cells from damage under hazard-
ous conditions, and their actions represent one of several de-
fense mechanisms that are operative in vivo. The low molec-
ular mass HSPs are considered to include HSPs with
molecular masses of 15^30 kDa. p20 was copuri¢ed with KB
crystallin and HSP27 from skeletal muscles, and it was iden-
ti¢ed as a member of the K crystallin low molecular mass HSP
family [1,2]. A high level of p20 is formed in normal skeletal
and heart muscles, as well as in smooth muscle tissue, and the
synthesis of this protein is not induced by heat or chemical
stress [3]. Two forms of p20, an aggregated form (p20-L) and
a dissociated form (p20-S), were identi¢ed in crude extracts of
muscles and both forms were puri¢ed to homogeneity [3]. p20-
S has a dimeric structure with covalent binding via a disul¢de
bond between subunits. However, p20 redistributes from a
cytosolic to an insoluble fraction and dissociates from an ag-
gregated form after heat stress [3]. It has recently been dem-
onstrated that cyclic nucleotide-dependent vasorelaxation is
associated with the phosphorylation of this protein [4]. How-
ever, the physiological role of p20 has not been clari¢ed. In
the present study, we investigated the e¡ect of p20 on platelet
function.
2. Materials and methods
2.1. Reagents
A dissociated form (p20-S) of p20, an aggregated form (p20-L) of
p20 and HSP27 were puri¢ed as described previously [3]. Bothrops
jararaca (snake toxin) was obtained from Sigma (St. Louis, MO,
USA) and botrocetin was puri¢ed from Bothrops jararaca by Fuji-
mura’s methods [5]. The other chemical substances were obtained
from Sigma (St. Louis, MO, USA).
2.2. Platelet aggregation using platelet-rich plasma
Human blood was donated from young healthy male volunteers
into one-tenth volume of a 3.8% solution of sodium citrate and cen-
trifuged for 12 min at 155Ug to obtain platelet-rich plasma (PRP).
The concentration of each agonist was chosen to induce about 60% of
the maximum aggregation in the control platelets: 2.5 WM ADP or 3.3
Wg/ml botrocetin. p20-S, p20-L and HSP27 were preincubated for 20
min with PRP. Platelet aggregation was followed in an aggregometer
(Aggrecorder II; DA-3220, Kyotodaiichi-Chemical, Kyoto, Japan) at
37‡C with a stirring speed of 800 rpm.
2.3. Platelet aggregation using ¢xed platelets
In order to further de¢ne the inhibitory e¡ect of p20 on platelet
aggregation induced by botrocetin, we used ¢xed platelets [6]. We
obtained ¢xed human platelets as follows: we mixed human PRP
with an equal volume of 2.0% paraformaldehyde and incubated the
mixture for 30 min at 22‡C. The platelets were then isolated by cen-
trifugation at 800Ug, washed twice with 3.8 mM HEPES-Tyrode’s
bu¡er (pH 6.7), and ¢nally suspended in the same bu¡er (pH 7.4), at a
¢nal concentration of 5U108 cells/ml. von Willebrand factor (vWF,
10 Wg/ml) was added to ¢xed platelets. Fixed platelets were stimulated
by botrocetin after preincubation with both p20-S (1.0 Wg/ml) and
vWF or in the absence of preincubation for 20 min with both p20-S
and vWF. The aggregation induced by 3.3 Wg/ml botrocetin was moni-
tored with the aggregometer described above.
2.4. Platelet aggregation ex vivo
Male hamsters (Gold, SLC, Japan) weighing 100^120 g were se-
lected and fed a standard chow (RC4, Oriental Yeast Co., Ltd., Ja-
pan). All animal experiments were performed in accordance with in-
stitutional guidelines. Hamsters were anesthetized by intraperitoneal
injection of pentobarbital (50 mg/kg), and p20-S (30, 100 and 300 Wg/
kg) was injected as a bolus (300 Wl) through the left jugular vein.
Blood (4.0 ml each) was collected by heart puncture in sodium citrate
(3.15%) 5 min after the bolus injection of p20-S. Platelet aggregation
induced by botrocetin (3.0 Wg/ml) using PRP was then investigated by
the same way as mentioned above.
2.5. Platelet aggregation using washed platelets
We investigated the e¡ect of p20 on platelet aggregation induced by
thrombin since thrombin is also a potent agonist for platelet aggre-
gation. Washed platelets were prepared as described previously [6].
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Human platelets were counted and adjusted to 4U108 cells/ml (¢nal
concentration). Washed platelet aggregation was induced by 0.3 unit/
ml thrombin after p20-S, p20-L or hsp27 were preincubated for 20
min. Aggregation in response to a stimulant was measured by the
aggregometer described above.
2.6. Statistical analysis
All data are expressed as the mean þ S.E.M. The signi¢cance of
drug e¡ects (*P6 0.01) was determined by ANOVA followed by the
Student Newman-Keuls test.
3. Results
We did experiments for platelet aggregation induced by
botrocetin or ADP using human PRP and investigated the
e¡ects of p20-S, p20-L and HSP27 on platelet aggregation.
When platelets were preincubated with p20-S for 20 min,
p20-S inhibited platelet aggregation dose-dependently induced
by botrocetin (Fig. 1), but not ADP. The treatment with p20
in the range between 10 and 100 Wg/ml caused similar reduc-
tion of platelet aggregation induced by botrocetin. HSP27 and
p20-L did not a¡ect botrocetin-induced platelet aggregation.
To de¢ne the inhibitory e¡ect of p20-S on platelet aggrega-
tion induced by botrocetin in further detail, we performed an
experiment using ¢xed human platelets since glycoprotein
(GP) Ib of platelet membrane is exposed by treatment with
2.0% paraformaldehyde [6]. Preincubation with p20-S (1.0 Wg/
ml) inhibited platelet aggregation by 58% as compared with
control (Fig. 2). However, in the absence of preincubation
with both p20 and vWF, the aggregation of platelets in re-
sponse to botrocetin was not inhibited.
Additionally, we performed platelet aggregation ex vivo
with PRP induced by botrocetin in hamsters. Platelet aggre-
gation was also inhibited by 58% when p20-S at a dose of 300
Wg/kg was administered intravenously (Fig. 3). In this case,
plasma concentration of p20-S determined at 5 min after an
intravenous bolus injection was 8.9 Wg/ml by a speci¢c immu-
noassay as described previously [3] and this level was esti-
mated to be enough for the reduction of platelet aggregation
since p20-S at a dose of 3.0 Wg/ml caused about 50% inhib-
ition on hamster platelet aggregation in vitro induced by bo-
trocetin (3.3 Wg/ml). When we also measured the level of p20
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Fig. 1. Dose response inhibition by p20-S of platelet aggregation in
human PRP. The aggregation of platelets stimulated by botrocetin
(3.0 Wg/ml) was performed after preincubation for 20 min with p20-
S or vehicle. Data represent the mean þ S.E.M. *P6 0.01 vs. con-
trol.
Fig. 2. Inhibition by p20-S of aggregation in human ¢xed platelets.
vWF (10.0 Wg/ml) was added to ¢xed platelets. The aggregation of
platelets stimulated by botrocetin (3.3 Wg/ml) was performed after
preincubation for 20 min with p20-S (1.0 Wg/ml) or vehicle.
Fig. 3. Dose response inhibition by p20-S of platelet aggregation in
hamster PRP. The aggregation of platelets stimulated by botrocetin
(3.0 Wg/ml) was performed after preincubation for 20 min with p20-
S or vehicle. Data represent the mean þ S.E.M. *P6 0.01 vs. con-
trol.
Fig. 4. Dose response inhibition by p20-S of washed platelet aggre-
gation in human. The aggregation of platelets stimulated by throm-
bin (0.2 units/ml) was performed after preincubation for 20 min
with p20-S or vehicle. Data represent the mean þ S.E.M. *P6 0.01
vs. control.
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in plasma of non-treated hamsters, it showed 4.2 þ 0.8 ng/ml
(n = 4).
In order to further clarify the role of p20-S on platelet
aggregation, we studied the e¡ect of p20-S on platelet aggre-
gation induced by thrombin, a physiological substance in the
blood Fig. 4. p20 inhibited platelet aggregation induced by
thrombin dose dependently in human washed platelets. How-
ever, p20-L and HSP27 did not inhibit platelet aggregation
induced by thrombin.
4. Discussion
HSPs are well recognized to protect cellular functions from
various damages. However, their physiological roles have not
been fully clari¢ed. In the present study, we investigated the
e¡ect of p20 on platelet activation, one of the HSPs with low
molecular mass, reporting for the ¢rst time that p20 inhibits
platelet aggregation in vitro.
We investigated the e¡ect of p20 on platelet aggregation in
vitro using PRP that was induced by ADP or botrocetin. p20-
S inhibited platelet aggregation induced by botrocetin, but not
ADP. p20-L or HSP27 did not prevent platelet aggregation.
We speculated that an aggregated form of p20 (p20-L) was
inactive and that p20-L was dissociated by some kind of stim-
ulation and changed to p20-S, an active form, for e¡ect on
platelets.
Botrocetin only stimulates the binding of vWF to platelet
GPIb, and then induces platelet aggregation. Therefore, it is
possible that the inhibition of platelet activation by p20-S is
related to the prevention of the vWF-GPIb axis. Additionally,
the result of an experiment using ¢xed platelets showed that
platelet aggregation induced by botrocetin was not observed
in the absence of preincubation by either p20-S or vWF. This
¢nding indicates that p20-S might interact with vWF but not
with platelet GPIb. Finally, we performed platelet aggregation
ex vivo using hamsters since the behavior of hamster platelets
is similar to human platelets [7^9]. An intravenous injection of
p20-S showed a dose dependent antiplatelet e¡ect. Therefore,
our ¢ndings make us speculate that p20 might play an inhib-
itory e¡ect on platelet activation in vivo.
However, botrocetin is not a physiological agonist in blood
circulation and we additionally investigated the e¡ect of p20
on platelet aggregation induced by thrombin. Thrombin is
well known to be a potent agonist for platelet aggregation
and recently interaction between thrombin and GPIb on
platelets has been reported and the fact that GPIb functions
as the high-a⁄nity platelet receptor for thrombin has been
shown [10^12]. Indeed p20-S completely prevented the platelet
aggregation induced by thrombin. These ¢ndings indicated
that p20 might have an important physiological role in blood
circulation. Moreover, in the clinical setting, plasma levels of
p20 in patients with acute dissecting aneurysm (0.66 þ 0.06 ng/
ml, n = 3) were higher than those of healthy subjects (6 0.06
ng/ml, n = 4). This observation also indicates that p20 actually
plays a role in physiological conditions in human. The results
promise a potential usefulness of p20 as antiplatelet strategy.
In our experiments, p20 did not prevent ADP-promoted
platelet aggregation. ADP stimulates platelets via its speci¢c
receptors on platelet membrane and this pathway is di¡erent
from that of botrocetin [13,14]. Therefore it seems unlikely
that p20-S interfered with platelet activation via ADP recep-
tors.
To the best of our knowledge, the present report is the ¢rst
to describe the function of p20 on platelet activation. In con-
clusion, these ¢ndings suggest that p20 can act intercellularly
to regulate platelet functions. Our results may provide the
basis for a novel aspect of a defensive system to thrombus
formation.
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